Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06239311

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Moderate to Severe Atopic Dermatitis Clinical Trial

Official title:
A Phase 3, Randomised, 2-arm, Parallel-group, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Subcutaneous Methotrexate Versus Placebo in Moderate to Severe Atopic Dermatitis.

Clinical Trial Summary

Atopic dermatitis is an ongoing condition that causes skin irritation, redness, and itchiness. Treatments are usually topical - applied to the skin (e.g., moisturisers or medicated creams) - but a wider variety of systemic treatments (that target the whole body) are needed for those whose condition does not improve with topical treatments. Methotrexate, a drug approved for similar conditions such as arthritis and psoriasis, has been shown to improve atopic dermatitis. This randomised, controlled clinical trial will investigate how effective.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06239311
Study type Interventional
Source medac GmbH
Contact
Status Not yet recruiting
Phase Phase 3
Start date February 2024
Completion date April 2026
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06012812 - A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT05549947 - Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis Phase 2
Recruiting NCT06136741 - A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis Phase 2
Recruiting NCT06099704 - Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
Completed NCT03568162 - Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT00148746 - Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis N/A
Recruiting NCT05702268 - Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis Phase 2
Recruiting NCT05997927 - Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis Phase 2
Not yet recruiting NCT05197023 - A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS Phase 1
Terminated NCT01286220 - Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis N/A
Completed NCT02426359 - Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients Phase 2